Division of Nephrology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan.
BMC Nephrol. 2013 Jan 16;14:16. doi: 10.1186/1471-2369-14-16.
S100A12 protein is an endogenous receptor ligand for advanced glycation end products. In this study, the plasma S100A12 level was assessed as an independent predictor of mortality, and its utility in clinical settings was examined.
In a previous cross-sectional study, plasma S100A12 levels were measured in 550 maintenance hemodialysis patients to determine the association between S100A12 and the prevalence of cardiovascular diseases (CVD). In this prospective study, the risk of mortality within a two-year period was determined. An integer scoring system was developed to predict mortality on the basis of the plasma S100A12 levels.
Higher plasma S100A12 levels (≥18.79 ng/mL) were more closely associated with higher all-cause mortality than lower plasma S100A12 levels (<18.79 ng/mL; P = 0.001). Multivariate Cox proportional hazards analysis revealed higher plasma S100A12 levels [hazard ratio (HR), 2.267; 95% confidence interval (CI), 1.195-4.302; P = 0.012], age ≥65 years (HR, 1.961; 95%CI, 1.017-3.781; P = 0.044), serum albumin levels <3.5 g/dL (HR, 2.198; 95%CI, 1.218-3.968; P = 0.012), and history of CVD (HR, 2.068; 95%CI, 1.146-3.732; P = 0.016) to be independent predictors of two-year all-cause mortality. The integer score was derived by assigning points to these factors and determining total scores. The scoring system revealed trends across increasing scores for predicting the all-cause mortality [c-statistic = 0.730 (0.656-0.804)]. The resulting model demonstrated good discriminative power for distinguishing the validation population of 303 hemodialysis patients [c-statistic = 0.721 (0.627-0.815)].
The results indicate that plasma S100A12 level is an independent predictor for two-year all-cause mortality. A simple integer scoring system was therefore established for predicting mortality on the basis of plasma S100A12 levels.
S100A12 蛋白是晚期糖基化终产物的内源性受体配体。在这项研究中，评估了血浆 S100A12 水平作为死亡率的独立预测因子，并研究了其在临床环境中的应用。
在之前的一项横断面研究中，测量了 550 例维持性血液透析患者的血浆 S100A12 水平，以确定 S100A12 与心血管疾病（CVD）患病率之间的关系。在这项前瞻性研究中，确定了两年内的死亡率风险。基于血浆 S100A12 水平开发了整数评分系统来预测死亡率。
较高的血浆 S100A12 水平（≥18.79ng/ml）与全因死亡率更高相关，而较低的血浆 S100A12 水平（<18.79ng/ml；P=0.001）。多变量 Cox 比例风险分析显示，较高的血浆 S100A12 水平[风险比（HR），2.267；95%置信区间（CI），1.195-4.302；P=0.012]、年龄≥65 岁（HR，1.961；95%CI，1.017-3.781；P=0.044）、血清白蛋白水平<3.5g/dL（HR，2.198；95%CI，1.218-3.968；P=0.012）和 CVD 病史（HR，2.068；95%CI，1.146-3.732；P=0.016）是两年全因死亡率的独立预测因子。整数评分通过给这些因素赋值并确定总分来确定。评分系统显示，随着总分的增加，预测全因死亡率的趋势[C 统计量=0.730（0.656-0.804）]。该模型在区分 303 名血液透析患者的验证人群方面具有良好的区分能力[C 统计量=0.721（0.627-0.815）]。
结果表明，血浆 S100A12 水平是两年全因死亡率的独立预测因子。因此，建立了一个简单的整数评分系统，基于血浆 S100A12 水平预测死亡率。
